Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity.

Campbell KM, Lin T, Zolkind P, Barnell EK, Skidmore ZL, Winkler AE, Law JH, Mardis ER, Wartman LD, Adkins DR, Chernock RD, Griffith M, Uppaluri R, Griffith OL.

Cell Rep. 2018 Aug 21;24(8):2167-2178. doi: 10.1016/j.celrep.2018.07.058.


Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.

Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R.

Oncotarget. 2017 Dec 28;9(3):4109-4119. doi: 10.18632/oncotarget.23751. eCollection 2018 Jan 9.


Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.

Hanna GJ, Adkins DR, Zolkind P, Uppaluri R.

Oral Oncol. 2017 Oct;73:65-69. doi: 10.1016/j.oraloncology.2017.08.008. Epub 2017 Aug 17. Review.


Checkpoint immunotherapy in head and neck cancers.

Zolkind P, Uppaluri R.

Cancer Metastasis Rev. 2017 Sep;36(3):475-489. doi: 10.1007/s10555-017-9694-9. Review.


Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.

Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS Jr, Adkins DR.

Clin Cancer Res. 2017 May 1;23(9):2186-2194. doi: 10.1158/1078-0432.CCR-16-1469. Epub 2016 Nov 9.


Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.

Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R.

Oral Oncol. 2017 Aug;71:169-176. doi: 10.1016/j.oraloncology.2016.09.010. Epub 2016 Oct 14. Review.


Unusual Cause of Stridor in an 80-Year-old Man.

Zolkind P, Non L, Chernock R, Ghogomu N.

Am J Med. 2016 Feb;129(2):e15-6. doi: 10.1016/j.amjmed.2015.09.011. Epub 2015 Oct 22. No abstract available.


The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB.

Ann Clin Lab Sci. 2014 Summer;44(3):241-8.


Supplemental Content

Loading ...
Support Center